Oncternal Therapeutics, Inc. Common Stock
ONCT
ONCT was delisted on the 2nd of December, 2024.
23 hedge funds and large institutions have $4.02M invested in Oncternal Therapeutics, Inc. Common Stock in 2020 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
10% more funds holding
Funds holding: 21 → 23 (+2)
0.72% more ownership
Funds ownership: 8.19% → 8.92% (+0.72%)
19% less capital invested
Capital invested by funds: $4.98M → $4.02M (-$961K)
29% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
IEQ Capital
Foster City,
California
|
+$269K |
| 2 |
DY
Dowling & Yahnke
San Diego,
California
|
+$93.9K |
| 3 |
Creative Planning
Overland Park,
Kansas
|
+$38.4K |
| 4 |
UCFA
United Capital Financial Advisors
Irving,
Texas
|
+$26.5K |
| 5 |
Renaissance Technologies
New York
|
+$23.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$18.7K |
| 2 |
Millennium Management
New York
|
-$10.7K |
| 3 |
ACM
Anfield Capital Management
Irvine,
California
|
-$8K |
| 4 |
Morgan Stanley
New York
|
-$3.58K |
| 5 |
NSIM
North Star Investment Management
Chicago,
Illinois
|
-$3.36K |
ONCT Hedge Fund Activity: Q1 2020 in Review
23 of the 4,548 institutional investors tracked by Wall St. Rank reported a position in Oncternal Therapeutics, Inc. Common Stock (ONCT) for Q1 2020, worth a combined $4.02M — down 19% from $4.98M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new ONCT positions and 1 closed out — a net gain of 2 holders — while 5 added to existing stakes and 7 trimmed.
The largest buyer was IEQ Capital, opening a new position worth an estimated $269K. The largest seller was Bank of America, cutting an estimated $18.7K.
- 23 institutional investors held Oncternal Therapeutics, Inc. Common Stock (ONCT) as of Q1 2020, up from 21 in Q4 2019.
- Funds reported $4.02M of Oncternal Therapeutics, Inc. Common Stock stock for Q1 2020, down 19% quarter-over-quarter.
- 3 funds opened new Oncternal Therapeutics, Inc. Common Stock positions in Q1 2020 and 1 closed out, a net change of +2 holders.
- The largest Oncternal Therapeutics, Inc. Common Stock buyer in Q1 2020 was IEQ Capital, an estimated $269K added.
- The largest Oncternal Therapeutics, Inc. Common Stock seller in Q1 2020 was Bank of America, an estimated $18.7K sold.
Based on aggregated 13F filings for Q1 2020.